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Purpose: In several species the retinal pigment epithelium (RPE) has the potential to transdifferentiate into retinal cells
to regenerate functional retinal tissue after injury. However, this capacity for regeneration is lost in mammals. The synthetic
retinoic acid derivative, fenretinide [N(4-hydroxyphenyl) retinamide], induces a neuronal-like phenotype in the human
adult retinal pigment epithelial cell line (ARPE-19). These changes are characterized by the appearance of neural-like
processes and the expression of neuronal markers not normally associated with RPE cells. Here we assess whether
fenretinide can induce a neuroretinal cell phenotype in ARPE-19 cells, by examining retinal cell marker expression.
Methods: ARPE-19 cells were treated daily with culture medium containing either 3 μM fenretinide or dimethyl sulfoxide
as a control for 7 days. Cells were processed for immunocytochemistry, western blotting, and for analysis by PCR to
examine the expression of a panel of RPE, neural, and retinal-associated cellular markers, including classical and non-
canonical opsins.
Results: Treatment with fenretinide for 7 days induced the formation of neuronal-like processes in ARPE-19 cells.
Fenretinide induced the expression of the cone long wavelength sensitive opsin (OPN1lw) but not rhodopsin (RHO), while
decreasing the expression of RPE cell markers. Many of the neuronal and retinal specific markers examined were expressed
in  both  control  and  fenretinide  treated  cells,  including  those  involved  in  photoreceptor  cell  development  and  the
multipotency of neural retinal progenitor cells. Interestingly, ARPE-19 cells also expressed both photoreceptor specific
and non-specific canonical opsins.
Conclusions: The expression of retinal-associated markers and loss of RPE cell markers in control ARPE-19 cells suggests
that these cells might have dedifferentiated from an RPE cell phenotype under standard culture conditions. The expression
of molecules, such as the transcription factors paired box 6 gene (PAX6), sex determining region Y-box 2 (SOX2), cone-
rod homeobox (CRX), and neural retina leucine zipper (NRL), further implies that in culture these cells are predisposed
toward a retinal progenitor-like state. The fenretinide-induced increase in photoreceptor cell markers, accompanied by a
decrease in RPE cell markers, suggests that retinoids may play a role in the transdifferentiation of RPE cells. Importantly,
our data show for the first time the expression of a vertebrate ciliary opsin (OPN1lw) and rhabdomeric-like opsin, opsin
4 (OPN4 also known as melanopsin) in a clonal cell line. Together these data suggest that ARPE-19 cells are primed for
and possess the capacity to differentiate toward a retinal cell-like lineage.
The retinal pigment epithelium (RPE), located between
the neurosensory retina and the choroid, is a monolayer of
cells vital for the maintenance of photoreceptor cell function
and  integrity.  The  RPE  also  plays  a  critical  part  in  the
development of the retina [1] and in some species participates
in the regeneration of functional neural retinal tissue after
injury [2] through RPE cell dedifferentiation, proliferation,
and redifferentiation into the cellular elements of the retina (a
process  termed  transdifferentiation).  Many  mature
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amphibians,  such  as  the  salamander  [3],  newt  [4,5],  and
Xenopus [6], are capable of this process throughout their lives,
while in birds it appears to be restricted to a limited period
during embryonic eye development [7]. Mammals have lost
the ability to regenerate the retina in vivo, although there is
evidence to suggest that embryonic RPE cells transplanted
into the adult eye are capable of forming retinal-like tissue
[8]  and  that  embryonic  RPE  cells  are  able  to  form  a
multilayered structure, expressing several retinal cell markers
after treatment with basic fibroblast growth factor (bFGF) in
culture [9].
To regenerate a complete retina, RPE cells must be able
to transdifferentiate into several cell types. Analysis of cells
from species where transdifferentiation has been shown to
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1701occur has revealed that RPE cells are capable of differentiating
into retinal ganglion, amacrine, photoreceptor, and glial cells
[5,9-11],  and  lens  [4].  Many  factors  have  been  shown  to
regulate  the  transdifferentiation  of  RPE  cells  into  neural
retina,  including  bFGF  [11],  insulin  [12],  neuroD  [13],
mitogen activated protein kinase extracellular signal related
kinase  (MEK)  [14],  and  neurogenin  [15].  Whereas
transforming growth factor (TGF)-β-like molecules, such as
activin, thought to be involved in RPE cell differentiation
[16], have been shown to block regeneration of the retina from
RPE [17].
Retinoid signaling is crucial during the early stages of eye
development  [18,19]  and  is  thought  to  promote  the
differentiation of photoreceptor cells [20]. Retinoic acid, a
transcriptionally active vitamin A derivative, plays an integral
role in the establishment of the retina and the specification of
cells.  Embryonic  exposure  to  retinoic  acid  increases  the
incidence of rod photoreceptor cells at the expense of cone
photoreceptors and amacrine cells in the zebrafish and rat
retina,  respectively  [21,22],  while  morpholino-mediated
knock-down  of  beta-carotene  15,15'-monooxygenase  1
(bcox), an enzyme critical to vitamin-A formation, in the
embryonic zebrafish results in abnormal photoreceptor cell
development [23].
It has previously been reported that retinoids have an
effect  on  the  differentiation  of  ARPE-19  cells,  a
spontaneously immortalized adult human RPE-derived cell
line, which has been widely used as a model system for the
study of RPE cells in vitro [24]. For example, treatment with
retinoic acid delays the appearance of RPE cell morphology
and the expression of RPE-specific genes peropsin, RPE65
and 11-cis retinal dehydrogenase [25]. Furthermore, there is
compelling  evidence  to  suggest  that  ARPE-19  cells  are
capable  of  differentiating  into  neuronal-like  cells  after
treatment with the synthetic analog of retinoic acid N-(4-
hydroxyphenyl)  retinamide  (fenretinide)  [26]  or  after
pretreatment with a neural stem cell media followed by 10
days  exposure  to  retinoic  acid  [27].  Following  retinoid
treatment, cells display neuronal-like elongated morphology
with  the  extension  of  multiple  processes.  Cells  were
characterized by immunocytochemistry and found to express
several  neuronal  cell  markers  after  fenretinide  treatment,
including  neurofilament  medium  polypeptide  (NF-M),
neurofilament  heavy  polypeptide  (NF-H),  calbindin  2
(CALB2),  neural  cell  adhesion  molecule  and  microtubule
associated protein 5 [26-28]. Furthermore, NSE and PAX-6
expression  dimethyl  sulfoxide  (DMSO)-treated  cells,
suggesting that ARPE-19 cells may act as a neural progenitor
cell line [28].
These  findings  suggest  that  a  mechanism  to  activate
transdifferentiation toward neural cells might exist, at least in
part, in human RPE cells and raises the possibility that RPE
could,  with  the  appropriate  manipulation,  be  induced  to
produce new retinal cell types, replacing those lost as a result
of  degenerative  disease.  Although  Amemiya  et  al.  were
unable to induce the expression of the retinal-associated cell
markers with retinoic acid using their protocol [27], the effects
of the synthetic analog of retinoic acid, fenretinide, on RPE
differentiation toward a neuroretinal cell fate have yet to be
examined. In this study we have used reverse transcriptase
PCR  (RT–PCR),  real-time  quantitative  PCR  (Q-PCR),
immunocytochemistry, and western blot analysis to examine
the effects of fenretinide on the expression of retinal cell
markers in ARPE-19 cells.
METHODS
Cell  culture:  ARPE-19  cells  (passage  22)  and  passage  2
human RPE cells (G.A. Limb, University College London,
London,  UK)  were  cultured  in  standard  culture  medium
containing Dulbecco's Modified Eagle's Medium and Ham's
F-12  Nutrient  Mixture  (DMEM/F12)  mix  (1:1)+
GlutaMAX™ with 1% penicillin–streptomycin and 10% fetal
bovine  serum  (FBS;  Invitrogen,  Paisley,  UK).  The
immortalized  RPE  cell  line  h1RPE7  was  also  cultured  in
Ham's  F-10  with  10%  heat-inactivated  FCS,  2  mM  l-
glutamine and 1% penicillin-streptomycin [29]. All cells were
incubated at 37 °C with 5% CO2. Cells were trypsinized and
passaged  onto  35-mm  uncoated  dishes  and  tissue  culture
flasks at a density of 2×103 cells/cm2. The following day cells
were  washed  with  warm  HEPES  Balanced  Salt  Solution
(Invitrogen), and the medium was replaced with low-serum
medium containing DMEM/F-12 (1:1)+ GlutaMAX™ with
1% penicillin–streptomycin and 3% charcoal–dextran-treated
FBS  (Perbio  Science  UK  Ltd.,  Thermo  Fisher  Scientific,
Northumberland, UK). The following day cells were washed
and  treated  with  low-serum  medium  containing  3  μM
fenretinide  (Tocris  Bioscience,  Bristol,  UK)  dissolved  in
DMSO  (Sigma-Aldrich  Company  Ltd,  Dorset,  UK).  This
treatment protocol was repeated once a day for a further 6
days. All handling of fenretinide was performed under low-
light conditions. Control cells were cultured under identical
conditions  in  low-serum  medium  with  the  addition  of  an
equivalent  volume  of  DMSO  (0.03%  volume  [v]/v)  only.
Phase  contrast  images  and  scanning  electron  micrographs
were taken following 7 days of treatment.
For  the  porcine  lens  capsule  membrane  (PLC)
experiments  the  lens  capsule  was  prepared  as  previously
described [30]. Briefly, the anterior lens capsule was isolated
from porcine eyes (Cheale Meats Ltd. Brentwood, UK). The
polyester  membrane  was  removed  from  a  Corning®
Transwell®  insert  (Sigma-Aldrich)  and  the  anterior  lens
capsule glued to the remaining plastic support. The anterior
lens capsule was carefully removed leaving the anterior lens
capsule membrane attached to the plastic support. The insert
was washed in Hanks Balanced Salt Solution containing 1%
Penicillin-Streptomycin and tested for sterility before seeing
of ARPE-19 cells. ARPE-19 cells were seeded onto tissue
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1702culture plastic or PLC and treated with DMSO or fenretinide,
as described above.
Reverse transcriptase PCR: Flasks of fenretinide-treated and
control cells were twice washed in 1 x Dulbecco’s phosphate-
buffered saline (2.7 mM KCl, 1.47 mM KH2PO4, 8.1 mM
NaCl  and  50.5  mM  Na2HPO4  -  PAA  Laboratories  Ltd.,
Yeovil, UK). TRIzol reagent (Invitrogen) was added to the
flasks and cells lysed by trituration. RNA was isolated with
chloroform induced phase separation and precipitated using
isopropanol as instructed by the manufacturers. The RNA was
treated  with  RQ1-RNase-free  DNase  (Promega,
Southampton, UK) to remove any contaminating DNA. First-
strand cDNA synthesis was performed on 3 μg of total RNA,
using Superscript III Reverse Transcriptase with an oligo-
(dT)20  primer  (Invitrogen)  at  50  °C,  according  to  the
manufacturer’s protocol. A reaction containing no reverse
transcriptase was also prepared for each RNA sample as a
control (-RT). Following cDNA synthesis all reactions were
treated  with  RNase  H  (Invitrogen)  to  degrade  the  RNA
template.  PCR  was  performed  on  the  first-strand  cDNA
synthesis  reaction  products,  using  GoTaq  polymerase
(Promega)  according  to  the  manufacturer’s  protocol  with
gene-specific  primers  (synthesized  by  Eurofins  MWG
Operon, Ebersberg, Germany) described in Table 1. The PCR
cycling parameters consisted of an initial denaturation step at
95 °C for 2 min, followed by 35 cycles of denaturation at 95 °C
for 30 s, annealing at primer melting temperature minus 3 °C
for 30 s and extension at 72 °C for 30 s, followed by a final
extension  step  at  72  °C  for  5  min.  PCR  products  were
separated on a 2% agarose gel and visualized using ethidium
bromide. A no template water PCR control was included for
each primer set.
Real-time  quantitative  PCR:  cDNA  was  prepared  from
ARPE-19  cells  as  described  above,  and  quantitative  PCR
performed  on  a  7900HT  Fast  Real-Time  PCR  System
(Applied Biosystems, Warrington, Cheshire, UK). Triplicate
PCR reactions were prepared using 1 μl cDNA with Power
SYBR  Green  PCR  master  mix  (Applied  Biosystems)  and
0.2 μM of gene-specific primer (Eurofins MWG Operon) in a
total volume of 25 μl. Primer sequences are contained in Table
1. Data were analyzed using SDS 2.2.2 (Applied Biosystems),
and raw fluorescence data were exported into the DART–PCR
spreadsheet  (version  1.0)  [31]  to  calculate  relative  gene
expression  normalized  to  the  geometric  mean  of
glyceraldehyde-3-phosphate  dehydrogenase  (GAPDH),  β-
tubulin, and β-2-microglobulin. The specificity of all primers
was assessed by gel electrophoresis of amplified products,
band sequencing, and examination of the dissociation curve.
The  effects  of  fenretinide  treatment  on  relative  mRNA
expression levels were assessed using SigmaStat 3.5 software
(Systat Software, Inc., Chicago, IL). Two-tailed Student t tests
were  performed  to  compare  expression  in  DMSO-  and
fenretinide-treated cells (n=4 per treatment group).
Immunocytochemistry: After 7 days of fenretinide or DMSO
treatment, cells were washed with 0.1 M PBS (138 mM NaCl,
3.89 mM KCl, 2.13 mM KH2PO4, 8.16 mM Na2HPO4) fixed
in 4% paraformaldehyde in PBS for 30 min at 4 °C and
blocked for 2 h at 4 °C in a PBS solution containing 0.3%
Triton X-100 (PBS-TX) and 5% normal donkey serum (NDS;
Stratech Scientific Ltd., Newmarket, UK). Cells were then
incubated overnight at 4 °C in PBS-TX containing 1% NDS
with primary antibodies raised in mouse: RHO clone 4D2
(1:100,  R  Molday,  University  of  British  Columbia,
Vancouver,  Canada),  KRT8  (1:2,000;  Millipore,  Watford,
UK), CRX (1:1,000; Abnova, Heildelberg, Germany), NSE
(1:50;  Cymbus  Biotechnology,  Hampshire,  UK),  SYP
(1:5,000; Millipore (UK) Ltd., Watford, UK), NF-M (1:1,000;
Millipore UK) and rabbit: NF-H (1:5,000; Millipore UK),
SCN1a  (1:1,000;  Millipore  UK),  PAX6  (1:300;  Covance,
Princeton, NJ), OPN1mw/lw (polyclonal antisera JH492; J.
Nathans, John Hopkins University, Baltimore, MD), CALB2
(1:1,000; Swant, Bellinoza, Switzerland), RCVRN (1:1,000;
Millipore  UK),  THY-1  (1:500;  Source  Bioscience
AUTOGEN,  Nottingham,  UK),  and  OPN4  (antiserum,
1:10,000  and  blocking  peptide  N-terminal  [15AA  NH2-
MNPPSGPRVPPSPTQ-COOH diluted at 100 ng/ml and pre-
absorbed overnight at 4 °C before application] I. Provencio,
University of Virginia, Charlottesville, VA). The following
day  cells  were  washed  in  PBS  before  incubation  with
appropriate  combinations  of  FITC-  or  TRITC-conjugated
antibodies (Stratech Scientific Ltd.) diluted at 1:200 in PBS-
TX  with  2%  NDS.  Cells  were  counterstained  with  4’6-
diamindino-2-phenylindole  dihydrochloride  (Sigma-
Aldrich), washed in PBS and mounted in Vectorshield (Vector
Laboratories Ltd., Peterborough, UK). Staining was imaged
and analyzed using a Zeiss 510 confocal microscope with
LSM  Image  Browser  software  (Joel  (UK)  Ltd.,  Welwyn
Garden City, UK). As a control for the specificity of secondary
antibodies, primary antibodies were omitted in some dishes.
Western  blot  analysis:  Flasks  of  fenretinide-  and  control
DMSO-treated cells were placed on ice, washed twice in cold
1X Dulbecco’s phosphate-buffered saline and harvested by
scraping in lysis buffer (10 mM HEPES, 1% Triton X-100,
150  mM  KCl,  1  mM  PMSF,  10  ng/ml  leupeptin,  1  mM
dithiothereitol  (DTT),  50  ng/ml  aprotonin,  10  mM  NaF,
100 μM sodium vanidate). The solutions were mixed at 4 °C
for 30 min on a tube rotator and centrifuged at 17,000 xg for
30  min.  The  aqueous  supernatants  were  isolated  and  the
protein concentration estimated using BioRad protein assay
reagent  (Biorad,  Hemel  Hempstead,  UK).  Samples  were
diluted 1:1 in Laemmli sample buffer and denatured at 95 °C
for 5 min. Equal amounts of protein were separated by sodium
dodecyl  sulfate  PAGE  (SDS–PAGE)  and  transferred  to
Hybond-polyvinylidene  fluoride  (PVDF)  membrane  (GE
Healthcare  Life  Sciences,  Buckinghamshire,  UK)  by
electrophoresis at 4 °C. Membranes were blocked at room
temperature for 1 h in blocking solution containing 10% milk
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1704in TBS-0.1% Tween-20 (TBS-T). Membranes were incubated
overnight at 4 °C in 10% milk/TBS-T containing primary
antibodies  raised  in  mouse:  CRX  (1:1,000;  Abnova)  and
KRT8 (1:2,000; Millipore UK); rabbit: CALB2 (1:10,000;
Swant),  OPN3  (1:500;  Abcam,  Cambridge,  UK),  PAX-6
(1:100;  Source  Bioscience  AUTOGEN,  Millipore  UK),
TUBB3 (1:2,000; Millipore UK), and OPN4 (1:10,000, I.
Provencio);  and  goat:  SOX2  (1:500;  Source  Bioscience
AUTOGEN). The following day membranes were washed
and  incubated  with  horseradish  peroxidase-conjugated
secondary  antibodies  (1:2,000;  Dako  UK  Ltd.,
Cambridgeshire, UK) in 1% milk/TBS-T for 2 h at room
temperature. Protein signal was detected by incubation in
LumiLight western blotting solution (Roche Products Ltd.,
Welwyn  Garden  City,  UK)  followed  by  exposure  to
autoradiographic film. Membranes were stripped using 8 M
guanidium-HCl  and  reprobed  with  anti-GAPDH  (1:1,000,
goat  polyclonal;  Everest  Biotech  Ltd.,  Oxfordshire,  UK).
Protein  levels  were  quantified  by  densitometry  using  the
ImageJ  processing  program  [32]  and  normalized  to  the
GAPDH  control  for  each  membrane.  Protein  levels  were
analyzed using SigmaStat 3.5 software. Two-tailed Student t
tests were used to compare protein levels in DMSO- and
fenretinide-treated cells (n=4 per treatment group).
RESULTS
Morphological changes induced by fenretinide: Initially we
examined morphological changes associated with fenretinide
treatment to ensure that the protocol used induced neuronal-
like differentiation in the ARPE-19 cells. Similar to previous
findings [26], cells cultured with DMSO appeared normal and
grew to confluence (Figure 1A). In contrast, cells treated with
3 μM fenretinide for 7 days exhibited dramatic morphological
changes characterized by an elongated appearance and the
emergence  of  neuron-like  processes  (Figure  1B).  Using
scanning  electron  microscopy  to  resolve  the  morphology
further,  we  observed  structures  reminiscent  of  neuronal
cultures, including the formation of varicosities along the
processes, the appearance of neurite-like branching/synaptic-
like appositions (Figure 1C-E), and the presence of lamellae
or ruffles at the “neurite” terminal (Figure 1F-G).
Analysis of gene expression in fenretinide-treated cells: To
test  for  the  presence  of  mRNA  expression  induced  by
fenretinide, we isolated RNA from fenretinide- or DMSO-
treated ARPE-19 cells, synthesized cDNA, and used a panel
of primers to amplify several photoreceptor-, neuroretinal-,
neuronal-, and RPE-specific cell markers in equal amounts of
cDNA by RT–PCR (Figure 2). Amplification products were
observed in both DMSO- and fenretinide-treated cells for
photoreceptor  cell  markers  Rcrvn,  Sag,  and  NR2e3  and
neuroretinal  cell  markers  Thy-1,  Opn4,  Calb2,  and  Gfap.
Opn3  (also  known  as  encephalopsin/panopsin),  a  non-
canonical  opsin  expressed  in  the  retina  and  other  tissues
throughout  the  body,  was  also  present  in  both  treatment
groups. The neuronal cell markers Nf-m, Nf-h, Nse, Syp, and
Tubb3 and the RPE cell markers Rlbp1, Krt8, Silv (also known
as Pmel17), and Rrh were expressed in cells with and without
fenretinide treatment, along with genes involved in retinal cell
differentiation, Pax6, Crx, and Nrl. Interestingly, primers used
to  amplify  both  cone  opsin  sequences  (Opn1mw  and
Opn1lw) produced a product only in the fenretinide-treated
cells; sequencing of the amplicon revealed it to be Opn1lw.
The retinal ganglion cell marker Brn3 was also amplified in
fenretinide-treated cells only. Transcripts for the RPE cell
markers Best1 and Tyr were not detected following fenretinide
treatment, and we were unable to detect Rho, Opn1sw, Irbp,
Rgr, or Rpe65 gene expression in either treatment group by
RT–PCR.
To address quantitative changes in gene expression, we
used Q-PCR to evaluate a select range of markers identified
in the initial PCR screen (Figure 3). There was a significant
increase  in  the  expression  of  the  Opn1mw/lw  transcript
(p<0.05) after fenretinide treatment, with complete absence
of amplification in the DMSO-treated cells. Opn3 and Krt8
were expressed in both treatment groups; however there was
a significant decrease in mRNA expression of both genes
following fenretinide treatment (p<0.05). Crx was amplified
in both treatment groups with no significant difference in the
levels  of  mRNA  expression  after  fenretinide  treatment
(p=0.42).  Rho    expression   was not quantifiable in  either
treatment group (data not shown).
Effect of fenretinide on protein expression in human retinal
pigment epithelial cells: We next investigated the effects of 7
days treatment with DMSO or fenretinide in ARPE-19 cells
on  protein  expression  by  immunocytochemistry.  Several
neuronal cell markers were expressed in ARPE-19 cells. The
expression of NSE was enhanced by fenretinide treatment,
particularly within the perinuclear region (Figure 4A). Both
control and fenretinide-treated cells expressed SYP, with a
wide distribution of staining throughout the control cells and
clear  staining  throughout  the  dendrites  after  fenretinide
treatment (Figure 4B). The voltage-gated Na+ channel SCN1a,
which functions in the initiation and propagation of action
potentials, was junctional in DMSO-treated cells. This pattern
of expression was not maintained after fenretinide treatment;
protein was localized to the nucleus, and sparse staining was
seen  along  cytoplasmic  extensions  (Figure  4C).  CALB2
staining was observed throughout the cytoplasm and along
dendrites after fenretinide treatment; in the control dishes
staining was less intense and perinuclear (Figure 4D). We then
examined retinal cell- and retinal progenitor cell-associated
markers. The expression of OPN1mw/lw was increased after
fenretinide treatment and was observed throughout the cell
(Figure 4E). Rhodopsin protein was not observed in ARPE-19
under  either  condition  (Figure  4F).  The  OPN4  antibody
detected  a  nuclear  signal  in  both  treatment  groups  with
punctate nuclear expression in control cells, which was more
Molecular Vision 2011; 17:1701-1715 <http://www.molvis.org/molvis/v17/a189> © 2011 Molecular Vision
1705intense after fenretinide treatment (Figure 4G). Pretreatment
with the OPN4 blocking peptide blocked the signal (data not
shown). TUBB3, a retinal cell-lineage marker found in early
phase retinal cells (cones, horizontal, amacrine, and retinal
ganglion  cells),  was  sparsely  distributed  throughout  the
DMSO-treated  cell  cytoplasm,  the  staining  intensity  was
increased after fenretinide treatment (Figure 4H). RCVRN
was observed in a few control cells but was increased after
fenretinide treatment; this was concurrent with a decrease in
KRT8 expression (Figure 4I). PAX6 and CRX staining was
detectable in the nucleus under both conditions but appeared
more  intense  after  fenretinide  treatment  (Figure  4J-K).
Negative  control  dishes,  where  the  primary  antibody  was
omitted, produced no signal (Figure 4L). One consequence of
treatment with fenretinide was a lower final density of cells
in the dish at 7 days. By plating ARPE-19 cells at various
densities  and  incubating  in  DMSO  containing  low-serum
media only, we were able to demonstrate that the changes in
ARPE-19 cell morphology and protein expression (CALB2)
observed  following  fenretinide  treatment  were  due  to
biochemical induction by fenretinide rather than differences
in final cell density (Figure 4M).
NF-H expression was observed in control-DMSO-treated
cells; however its expression varied. In the same dish we
observed patches of cells with low and high levels of NF-H
expression  (Figure  5A).  Fenretinide  treatment  increased
levels of expression across the dish with strong staining along
the cellular projections. Similarly, NF-M expression was also
observed in a small percentage of control cells with increased
levels of expression observed after 7 days treatment with
fenretinide. To ascertain whether the expression of neuronal
cell markers is a phenomenon specific to ARPE-19 cells in
culture, we examined neuronal protein expression in cultured
passage 2 human RPE cells and in the immortalized human
Figure 1. Fenretinide treatment induces
a neuronal-like phenotype in ARPE-19
cells.  Cells  were  treated  on  uncoated
tissue  culture  plastic  with  media
containing dimethyl sulfoxide (A) or 3
μM fenretinide (FR; B) once a day for 7
days,  and  the  morphology  was
examined  by  phase  microscopy.  C:
Scanning electron microscopy of FR-
treated cells shows neural processes and
the  formation  of  varicosities  and
neurites  (highlighted  in  the  dashed
boxes and shown at high magnification
in D and E, respectively). F: Synaptic-
like appositions were also present at the
neurite  terminal,  shown  at  high
magnification in G. Scale bars equal 200
μm in A and B, 100 μm in C, 4 μm in
D, 20 μm in F, and 2 μm in E and G.
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1706RPE  cell  line  h1RPE7  (Figure  5B).  We  observed  strong
cytosolic  expression  of  NF-H  in  primary  RPE  and  in
approximately  50%  of  h1RPE7  cells.  Similarly,
synaptophysin expression was observed in both passage 2
RPE and h1RPE7 cells. The expression of neuronal markers
NF-M/H was decreased in ARPE-19 cell by culture on PLC,
a surface conducive to RPE cell differentiation [30] (Figure
5C). Culturing cells on PLC also prevented the fenretinide-
induced increase of NF-M and NF-H in ARPE-19 cells.
Protein expression changes induced by fenretinide were
examined  in  whole  cell  extracts  by  western  blot  analysis
(Figure 6). A single band of the correct molecular weight was
detected for each protein except for OPN4, where multiple
bands were detected. In this instance we used a blocking
Figure 2. Analysis of cell markers in
ARPE-19 cells by reverse transciptase
PCR. Dimethyl sulfoxide (DMSO)- and
fenretinide  (FR)-treated  cells  express
mRNAs  normally  associated  with
neuronal and retinal cells in culture and
lose retinal pigment epithelium (RPE)
cell  markers.  mRNA  expression  was
detected in DMSO- and FR-treated cells
using reverse transcriptase PCR. Primer
pairs  based  on  human  opsins,  and
retinal, neuronal, and RPE cell marker
sequences  were  used  to  amplify
products from equal amounts of cDNA.
A no-template RNA control (NTC) and
a reaction lacking reverse transcriptase
(-RT)  was  included  for  each
amplification. Tbp was amplified as a
positive loading control.
Figure 3. Quantitative analysis of gene
expression  in  human  retinal  pigment
epithelial cell line (ARPE-19) cells after
fenretinide  treatment.  Real-time  PCR
was employed to examine quantitative
differences  in  mRNA  expression
between dimethyl sulfoxide (DMSO)-
and fenretinide (FR)-treated cells. Data
shown  are  mean  relative  expression
levels±standard error of the mean after
normalization to the geometric mean of
Gapdh, Tubb, and β2m (n=4).
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1707peptide to identify the specific band (Figure 7). Individual
bands were analyzed by densitometry and quantified relative
to  a  GAPDH  loading  control.  Fenretinide  induced  a
significant increase in the expression of CRX, OPN4, and
CALB2 proteins (all p<0.05, Student t test) and a decrease in
the expression of OPN3 and KRT8 (p<0.001 and p<0.01,
respectively,  Student  t  test).  We  found  no  significant
difference in the expression of PAX6 or SOX2 by western blot
following  fenretinide  treatment  (p=0.476  and  0.180,
respectively).
DISCUSSION
Previous studies have shown that the human RPE cell line,
ARPE-19,  is  capable  of  developing  neuronal  cell-like
characteristics  following  treatment  with  fenretinide.  The
phenotypic changes were accompanied by an increase in non-
retinal specific neuronal cell markers. Given that ARPE-19
express neuronal cell markers after treatment with fenretinide,
we  have  investigated  the  potential  for  transdifferentiation
toward a retinal phenotype in this cell line by examining the
expression  of  retinal-associated  markers  after  fenretinide
treatment.
Following 7 days of treatment with 3 μM fenretinide,
cells  were  morphologically  similar  to  neurons,  with  an
elongated cell body and the formation of neurite branching.
Confirming previous findings [26,28], we found that neuronal
cell markers were upregulated in fenretinide-treated cells. We
Figure 4. Immunocytochemical analysis of neuronal and photoreceptor cell markers in ARPE-19 cells after treatment with dimethyl sulfoxide
or fenretinide. A-K: ARPE-19 cells were treated with 3 μM fenretinide or DMSO and processed for immunocytochemistry. The nuclei of
cells are stained with 4',6-diamidino-2-phenylindole (blue) with the exception of cells where protein expression was detected within the nucleus
(OPN4, CRX, and PAX6). Staining is indicated by the text color. L: Staining was not detected in control plates where only secondary antibodies
were used. M: Final cell density did not affect cell morphology or changes in protein expression. ARPE-19 cells were seeded at various
densities (i, 0.5×103; ii, 1×103; and iii, 2×103 cells/dish) and cultured for 7 days in DMSO-containing medium before staining for CALB2
(red). All scale bars are 50 μm.
Molecular Vision 2011; 17:1701-1715 <http://www.molvis.org/molvis/v17/a189> © 2011 Molecular Vision
1708Figure 5. Neuronal markers are expressed in retinal pigment epithelium cells in culture but are lost after culture on a porcine lens capsule
membrane (PLC). The expression of neurofilament heavy and medium polypeptides (NF-H and NF-M respectively) varied in dimethyl
sulfoxide (DMSO)-treated cells. A: The first two panels show the variation of NF-H expression within the same dish of DMSO-treated
ARPE-19 cells, which is increased across the whole dish after fenretinide (FR) treatment. Similarly, the expression of NF-M varies within
cells of the same field and is increased by fenretinide. B: Passage 2 primary human RPE cells and an additional human RPE cell line (h1RPE7)
express the neuronal markers NF-H and synaptophysin (SYP). C: Culturing ARPE-19 on a PLC decreases the expression of neuronal markers
in control cells and prevents the fenretinide-induced increase of neuronal markers. Protein staining is indicated by the color of the text (red
or green). All scale bars equal 50 μm.
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1709also  found  that  DMSO-treated  control  ARPE-19  cells
expressed many of the neuronal cell markers examined, such
as  SYP,  NSE,  NF-M,  NF-H,  CALB2,  and  TUBB3.
Mammalian adult RPE cells have been shown to switch on
TUBB3 within 5 days of primary culture and a multitude of
neuronal progenitor and neuronal markers within 3 passages
in culture [33,34]. ARPE-19 cells are a highly proliferative
cell line that have lost several key RPE cell characteristics,
including pigmentation, the typical RPE cell cobblestone-like
morphology, junction formation [24], and many key RPE
proteins  critical  to  normal  cell  function  [35,36].  Loss  of
phenotypic  characteristics,  such  as  enzyme  activity  and
polarization, is not limited to the ARPE-19 cell line, it has also
been demonstrated in the human D407 RPE cell line [37].
Although previous studies have shown that ARPE-19 cells
express RPE65 mRNA transcripts [24,25], RPE65 protein has
yet to be observed [36]. The loss of RPE cell markers and
phenotype  accompanied  by  expression  of  neuronal  cell
markers in RPE cells suggests that cells de-differentiate away
from the fully differentiated RPE cell phenotype in culture.
Subsequent to retinal injury in amphibians, RPE cells re-
enter the cell cycle and proliferate into de-differentiated cells,
losing  pigmentation  and  many  RPE-specific  genes,  while
gaining neuronal and retinal progenitor cell markers [38,39].
ARPE-19  cells  appear  to  have  undergone  this  initial
transformation under normal culture conditions. We found
that many genes involved in the differentiation of the neural
retina  are  expressed  in  ARPE-19  cells,  including  Crx,  a
homeobox transcription factor expressed in developing and
mature  photoreceptor  cells,  which  is  required  for
photoreceptor differentiation, [40] and NRL, a leucine zipper
transcription  factor  involved  in  the  development  of,  and
expressed  predominantly  in,  rods  [41].  These  two
transcription factors bind with the orphan nuclear receptor
NR2E3 to regulate photoreceptor cell differentiation [42]. The
presence of these factors in ARPE-19 cells under normal
culture conditions suggest that they are predisposed toward a
photoreceptor cell phenotype. Previous studies have shown
that Crx is upregulated in human retinoblastoma cells after
treatment with retinoids [43,44], and here we show that a
synthetic retinoic acid also increases CRX gene and protein
expression in human RPE cells.
ARPE-19 cells express several key transcription factors
implicated  in  the  maintenance  of  retinal  progenitor  cell
multipotency, including PAX6 [45] and SOX2 [46]. PAX6, a
master  control  transcription  factor  essential  for  normal
development of the eye, is sufficient to induce proliferation,
depigmentation, and neuronal gene expression in chick RPE
cells [47]. PAX6 has been identified in transdifferentiating
nonpigmented RPE [48], developing RPE [49], cultured adult
RPE, and in human embryonic stem cell-derived RPE cells in
vitro  [35]  but  not  in  vivo  [35,48].  The  multipotency  of
Figure  6.  Detection  of  protein
expression  in  ARPE-19  cells  after
dimethyl  sulfoxide  or  fenretinide
treatment by western blot analysis. Cells
were treated with 3 μM fenretinide (FR)
or  dimethly  sulfoxide  (DMSO)  for  7
days and extracts prepared for western
blot.  Equal  amounts  of  protein  were
loaded onto a sodium dodecyl sulfate
PAGE  gel,  transferred  to  membrane,
and  probed  with  antibodies  generated
against  cone  rod  homeobox  (CRX),
opsin 3 (OPN3), melanopsin (OPN4),
calbindin  2  (CALB2),  cytokeratin  8
(KRT8), paired box 6 (PAX6), and sex
determining  region  Y-box  2  (SOX2).
Proteins  were  detected  using
chemiluminescence  and  visualized
using  autoradiographic  film.
Membranes were stripped and reprobed
with  glyceraldehyde  3-phosphate
dehydrogenase (GAPDH) as a loading
control.  Representative  blots  from
DMSO- and FR- treated cells are shown.
Protein  levels  were  quantified  using
densitometry and normalized relative to
the  GAPDH  loading  control.  Data
shown are mean±standard error of the
mean normalized to GAPDH (n=4).
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transcription factor associated with the proliferation of neural
retina progenitor cells [46] and pluripotency [50,51]. Our
findings,  showing  that  PAX6  and  SOX2  are  present  in
ARPE-19 cells, suggest that these cells retain plasticity in
terms of their capacity to differentiate.
While  the  expression  of  neuronal  cell  markers  has
previously been reported in ARPE-19 [28], these are the first
data to demonstrate the presence of retinal cell-associated
markers in a mammalian RPE cell line. Many of the retinal
cell  markers  we  examined  are  detectable  under  control
conditions  in  ARPE-19  cells,  including  markers  for
photoreceptors,  and  neuroretinal  cells,  including  retinal
ganglion  cells,  amacrine  cells,  and  retinal  astrocytes.
Importantly, fenretinide was able to induce the expression of
the red cone opsin Opn1lw in ARPE-19 cells, which is the first
report of such an occurrence in a mammalian RPE cell line;
however we were unable to detect rhodopsin expression in
either group. It is possible that fenretinide treatment does not
induce the expression of rhodopsin in these cells, similar to
Figure 7. A melanopsin (OPN4) peptide-blocking experiment was
performed to test the specificity of the antibody for western blot. Due
to the presence of multiple bands on the OPN4 western blot the OPN4
antibody was pre-incubated with a fivefold excess of 15 amino acid
N-terminal blocking peptide in 10% milk/TBS-T for 2 h at room
temperature  before  hybridization.  Proteins  extracted  from
fenretinide (FR) and dimethyl sulfoxide (DMSO) treated cells were
incubated  with  OPN4  antibody  pre-incubated  with  the  blocking
peptide (OPN4+BP) or OPN4 antibody alone. A single band of
approximately 70 kDa specific to OPN4 was absent in the western
blot containing the blocking peptide.
findings after retinoic treatment in retinoblastoma cells by Li
et al. [44]. We suggest that the retinoid treatment performed
in the current study may be conducive to cone differentiation,
while inhibiting rod gene expression. Alternatively, the lack
of  detectable  rhodopsin  may  reflect  a  conserved
developmental  timing  system  where  the  differentiation  of
retinal cells in culture reflects that observed in vivo during
development [52].
The RPE expresses many visual pigment-like proteins
despite its apparent lack of light responsiveness. Our finding
that  melanopsin  (OPN4)  is  expressed  in  ARPE-19  cells
together with Opn1mw/lw is of significant interest as unlike
the latter, melanopsin is a novel photopigment that shares a
common  ancestry  with  invertebrate  rhabdomeric  proteins
[53].  Unlike  the  classic  visual  opsins,  melanopsin  is  not
thought to be expressed in rod and cone cells in the retina,
instead its expression is restricted to networks of intrinsically
photoreceptive  retinal  ganglion  cells  (ipRGCs)  where  it
functions  in  nonimage-forming  light  responses  [54-56].
Expression  of  melanopsin  mRNA  has  previously  been
reported in the RPE cells of Xenopus [57], mouse [58], and
humans; however for the latter it was suggested that this could
be attributed to retinal contamination during dissection of
tissues  [59].  This  is  the  first  reporting  of  melanopsin
expression in a human cell line; however immunoreactivity is
confined to the nucleus, whereas it is localized throughout the
cell membrane of ipRGCs in the rodent, primate, and human
retina [56,60] and after overexpression in the human RPE cell
line D407 [61]. Although melanopsin expression is increased
by fenretinide in our cells staining for the RGC marker, BRN3
was not detected (data not shown). Previous findings have
suggested  that  BRN3  is  not  required  for  the  initial
specification of RGCs, but it is needed for maturation of RGC
cells [62]. The absence of BRN3 staining may reflect the
transdifferentiation of cells toward an immature RGC, which
might  also  explain  the  discrepancy  in  the  localization  of
melanopsin. Alternatively, nuclear expression of melanopsin
in the ARPE-19 cells line could indicate that the cells do not
produce a mature form of the protein, which localizes to the
plasma membrane [61]. Given these findings, the ARPE-19
cell line could prove to be a useful model for the study of
melanopsin trafficking in human cells.
Other non-canonical opsins are also expressed outside of
the  photoreceptor  cell  layer  of  the  retina.  Human
encephalopsin (Opn3) is a novel opsin of unknown function
expressed in a wide range of non-neuronal tissues and the
brain  and  retina  [63].  In  the  eye  it  is  present  from  early
developmental stages to adulthood [64]. Here we show that
encephalopsin is expressed in ARPE-19 cells and that both
mRNA  and  protein  levels  are  decreased  after  fenretinide
treatment, which suggests that differentiation away from the
epithelial cell type is not conducive to its expression. As yet
Opn3 has not been identified in RPE cells in vivo.
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are expressed in RPE cells in vivo. RRH retinal pigment
epithelium-derived rhodopsin homolog (peropsin) is localized
within the microvilli of RPE cells [65] where it is thought to
act as a photoisomerase [66]. A previous study has shown that
retinoic acid can delay the expression of RRH in ARPE-19
cells for up to 5 weeks [25]; however expression of the Rrh
gene in our cells was unaffected by fenretinide treatment,
which again suggests that either the synthetic retinoid may act
on a different signaling pathway or that the passage number
of ARPE-19 cells is a key factor in the regulation of some
RPE-specific genes in culture. RGR opsin is a G protein-
coupled receptor found in RPE and Muller cells [67] and acts
as  a  photoisomerase,  converting  all-trans  retinal  to  11-cis
retinal [68]. We were unable to detect Rgr mRNA expression
in  ARPE-19  cells.  This  absence,  which  has  also  been
described  previously  [69],  provides  further  evidence  to
suggest that ARPE-19 cells are in a de-differentiated state.
Recently, Samuel et al. identified a signaling pathway
responsible for fenretinide-induced neuronal differentiation
of ARPE-19 cells [70]. Fenretinide treatment was shown to
activate the signaling kinases c-Raf and MEK1/2 in cells,
while blocking MEK1/2 with inhibitors and small interference
RNA (siRNA) prevented neuronal differentiation. The MEK
pathway  regulates  many  cellular  processes,  including
proliferation and differentiation. Importantly, this pathway
has also been implicated in the transdifferentiation of RPE to
retina in vivo in adult newt Xenopus larvae and chick embryo
[14,71,72].
The possibility of using transdifferentiated human RPE
cells  for  the  treatment  of  retinal  disease  is  somewhat
controversial.  Clinical  treatments  for  retinal  degenerative
diseases,  resulting  in  the  loss  of  photoreceptor  cells,  are
extremely  limited  at  present.  Recently,  there  has  been  an
increased interest in the development of cell-based therapies,
which aim to either halt the progression of photoreceptor cell
death or replace cells lost as a consequence of disease. To
induce the transdifferentiation of a patients’ own RPE cells to
form a fully functional retina, as observed in other species,
would be an ideal solution to treat many forms of retinal
degeneration.  Although  the  transdifferentiation  of
mammalian RPE cells into retinal cells does not naturally
occur in vivo, it might be possible to manipulate this process
after retinal injury. It would therefore be interesting to view
the effects of fenretinide treatment in the eye after retinal
injury or in a degenerating animal model. The PLC will also
provide a useful in vitro model system to study the effects of
the  microenvironment  on  fenretinide-induced
transdifferentiation of RPE cells. Although not the natural
substrate of RPE, the PLC could be used to provide clues as
to the identity of signaling molecules required for, or the
mechanisms  preventing  transdifferentiation  of  mammalian
RPE in vitro and RPE cell differentiation in vivo in response
to injury.
In this study we have demonstrated that in vitro ARPE-19
cells have the potential to differentiate toward a retinal cell
lineage.  At  this  stage  it  is  unclear  whether  complete
transdifferentiation, as specified by the formation of a fully
functional cell, is a possibility. It is unlikely that the signals
required for full transdifferentiation of cells are present in a
tissue culture dish, and ultimately the local microenvironment
of the damaged retina would be expected to play a key role in
directing  cell  fate.  A  comparative  analysis  of  the  RPE
response to retinal injury between species is imperative to
identify the transdifferentiation signaling pathways absent in
most vertebrates.
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